Skip to main content
Equibles

Walleye Capital LLC

Position in ALLO — Allogene Therapeutics, Inc.

CIK 1758720 NEW YORK, NY
Back to ALLO Full portfolio

Position in ALLO

as of Jun 30, 2026 · filed Aug 3, 2026
Position Value
$6,797,464
+$6,574,655 QoQ
Shares Held
3,268,012
+4608.2% QoQ
Ownership
0.946%
of shares outstanding
% of Portfolio
0.05%
of 13F equity value
Holder Rank
#27
of 209 holders
Holding Since
Jun 2020
5 quarters on record
Voting authority Sole 100% Shared 0% None 0%

Common Shares in ALLO Over Time

Shares Held

Position Value (USD)

Derivatives in ALLO

reported options exposure · as of Jun 30, 2023
CallValue
$18,886
CallShares
3,800
PutValue
$0
PutShares
0

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Jun 30, 2026

Walleye Capital LLC holds $328,656,270 across 126 Biotechnology names. ALLO ranks #15 (2.1% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 ASND
Ascendis Pharma A/S
 126,005 $33,608,053
2 CYTK
Cytokinetics Inc
 239,728 $20,422,428
3 BMRN
Biomarin Pharmaceutical Inc
 288,233 $16,492,692
4 IDYA
IDEAYA Biosciences, Inc.
 386,183 $14,393,040
5 REGN
Regeneron Pharmaceuticals, Inc.
 22,596 $14,089,509
6 RARE
Ultragenyx Pharmaceutical Inc.
 334,854 $11,180,775
7 TYRA
Tyra Biosciences, Inc.
 347,898 $11,111,862
8 BCAX
Bicara Therapeutics Inc.
 353,226 $10,487,279

All Filings in ALLO

Export CSV
6 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $6,797,464 3,268,012
2023-12-31 $222,809 69,411
2023-06-30 $18,886 3,800
2023-06-30 $571,709 115,032
2023-03-31 $510,968 103,435
2020-06-30 $708,071 16,536